Source: International Congress 2014 – Asthma and COPD devices and treatments
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
F. Kanniess, G. Hanf, M. Hosoe, A. M. Tanase, S. Vaidya, R. Banerjee, B. Hederer (Reinfeld, Berlin, Germany; Basel, Switzerland; Cambridge, United States Of America; Hyderabad, India). Mometasone furoate delivered via the Breezhaler^® and Twisthaler^® devices in asthma. Eur Respir J 2014; 44: Suppl. 58, 915

Member's Comments

No comment yet.

Related content which might interest you: Plume temperature and force of fluticasone propionate/formoterol pMDI compared with fluticasone propionate/salmeterol pMDI Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014 Lung deposition analysis of two formulations of fluticasone/salmeterol HFA pMDI in stable asthma patients Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 Once-daily tiotropium respimat add-on to ICS±LABA improves control across asthma severities Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Mixed treatment analysis comparing tiotropium HandiHaler® and Respimat® Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 High dose extrafine beclomethasone/formoterol via metered dose inhaler is effective and safe in asthmatics not controlled on medium-high dose of inhaled corticosteroids Source: International Congress 2014 – Asthma and COPD management Year: 2014 Mometasone furoate delivered via Breezhaler and Twisthaler in patients with asthma Source: International Congress 2019 – Asthma: outcomes of clinical trials and cohorts Year: 2019 Tiotropium respimat: Comparison of bronchodilator efficacy of 5 and 2.5 µg doses Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Pharmacokinetics (PK) of indacaterol acetate and mometasone furoate delivered alone or in combination following once daily inhalation in healthy subjects Source: International Congress 2014 – Asthma and COPD management Year: 2014 Pharmacokinetics (PK), safety and tolerability of abediterol and mometasone furoate fixed- and free-dose combinations in healthy subjects Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 Dose-proportional lung bioavailability of beclometasone dipropionate and formoterol fumarate across three different dose strenghts of CHF1535 pMDI Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013 Efficacy and safety of indacaterol acetate on ICS background therapy in asthma Source: International Congress 2014 – Asthma and COPD management Year: 2014 In vitro lung deposition of fluticasone propionate/formoterol (FP/FORM) pressurized metered dose inhaler (pMDI) with different inhalation profiles Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Once-daily tiotropium Respimat add-on to at least ICS in adult patients with symptomatic asthma: Pooled safety analysis Source: International Congress 2014 – Asthma and COPD management Year: 2014 Plume characteristics of fluticasone propionate/formoterol pMDI compared with fluticasone propionate/salmeterol pMDI Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013 Interaction between aclidinium bromide and formoterol fumarate in small human airways Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 Evaluation of systemic exposure between two nasal spray formulations of mometasone furoate in healthy subjects Source: Annual Congress 2013 –Treatment of asthma Year: 2013 Effect of inhaled vilanterol trifenatate/fluticasone furoate on breathing pattern, dyspnea and respiratory muscle function in severe COPD Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases Year: 2014 24-h efficacy and pharmacokinetics of tiotropium Respimat® 5 μg in patients with asthma Source: International Congress 2015 – Immune mechanisms in the human lung Year: 2015 Formoterol Aerolizer inhaler technique in patients with Asthma and COPD Source: International Congress 2017 – Pulmonary drug and devices delivery Year: 2017 Interaction between RPL554 and glycopyrronium bromide in small human airways Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014